Navigation Links
Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
Date:12/14/2007

BALTIMORE, Dec. 14 /PRNewswire/ -- Alba Therapeutics Corporation announced today that it has entered into a strategic collaboration with Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ), to jointly develop AT-1001, Alba's lead inhibitor of barrier dysfunction in various gastrointestinal ("GI") disorders. Shire will receive rights to commercialize all forms of AT-1001 outside of the United States and Japan. Alba will retain all rights to commercialize AT-1001 in the United States and Japan.

Under the terms of the collaboration, Alba will receive an initial, non- refundable licensing payment of US$ 25 million. Joint development costs toward global approval of AT-1001 will be shared 50/50 after the completion of two Phase 2 studies for Celiac disease. Alba is eligible to receive over US$ 80 million if certain clinical, regulatory and launch milestones are met for certain GI indications. Additional milestone payments totaling over US$ 40 million per indication will also be payable to Alba if the Collaboration is expanded beyond GI indications. Alba is also eligible to receive up to US$ 220 million in sales-based milestones, as well as tiered royalties. Not including royalties and cost sharing, the deal is valued at over US$ 325 million if all milestones are achieved.

Dr. Blake M. Paterson, Alba's President & CEO said:

"We are pleased to enter into this partnership with Shire, which leverages the unique experience and expertise of both companies in developing therapies for GI disorders. The combination of Alba's barrier function technology and autoimmune development capabilities with Shire's proven track record in GI drug development and commercialization will greatly enhance our efforts to bring these novel therapies to patients."

Matthew Emmens, Shire's CEO said:

"Alba's products have the potential to be an excellent addition to our current gastrointestinal business. This technology should provide significant benefit to patients w
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... CannLabs, Inc. (OTCQB: CANL), the leading ... methodologies relating to cannabis, today announced that it has ... from an existing stockholder of the Company. , ... from one of our existing stockholders,” stated Mark ... help accelerate our planned expansions into the Connecticut and ...
(Date:11/22/2014)... November 21, 2014 On November 17th ... the 2014 Emerging Medical Technologies Summit in San Francisco ... Widely regarded among Silicon Valley investors and technology ... innovation, the win also positions Briteseed to move ... competition in 2015 and compete with other elite innovation ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 Respiratory ... simulate the proper management of life-like respiratory ailments ... lung devices . Grand Rapids-based, Michigan Instruments Inc. ... donate two of the respiratory simulation units to ... each. Grand Valley and Muskegon Community College are ...
(Date:11/22/2014)... 21, 2014   ... Commercial Officer zu KLOX    ... Chief Financial Officer bestellt    KLOX ... seines jüngst zugelassenen Behandlungssystems zur Wundheilung zu beginnen    ... "Unternehmen") ist sehr erfreut, die folgenden personellen Veränderungen anzukündigen: ...
Breaking Biology Technology:CannLabs Secures $750,000 Line Of Credit 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 3KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5
... Iowa, Dec. 18 - DuPont today congratulated,growers planting ... of,the 15 national categories in the 2007 National ... these growers won with Pioneer sorghum,hybrid 84G62., ... in all,five national contest segments. First-, second- and ...
... PALO ALTO, Calif., Dec. 18 CV Therapeutics,Inc. ... U.S. Food and Drug,Administration (FDA) has approved new ... tablets) which describes the ability,of ranolazine to inhibit ... Published data on ranolazine,s mechanism suggests that during ...
... Md., Dec. 18 Panacea Pharmaceuticals, lung,cancer ... one of Time Magazine,s,Ten Biggest Medical Breakthroughs ... please cut,and paste into browser:, http://www.time.com/time/specials/2007/top10/article/0,30583,1686204_1686252_1690390, ,00.html) ... to facilitate the identification,of lung cancer, even ...
Cached Biology Technology:DuPont Congratulates Growers Planting Pioneer(R) Brand Sorghum Hybrids in Winning Majority of National Categories in Yield Contest 2FDA Approves New Mechanism of Action Labeling for Ranexa(R) 2Panacea Pharmaceuticals' Lung Cancer Diagnostic Test, LC Detect(SM), Named One of Time Magazine's Ten Biggest Medical Breakthroughs of 2007 2Panacea Pharmaceuticals' Lung Cancer Diagnostic Test, LC Detect(SM), Named One of Time Magazine's Ten Biggest Medical Breakthroughs of 2007 3Panacea Pharmaceuticals' Lung Cancer Diagnostic Test, LC Detect(SM), Named One of Time Magazine's Ten Biggest Medical Breakthroughs of 2007 4
(Date:11/10/2014)... pods began appearing on U.S. store shelves in early ... ever since. The small packets can be tossed into ... a liquid or powder. The convenience, though, has come ... from researchers at Nationwide Children,s Hospital found that from ... of 17,230 children younger than 6 years of age ...
(Date:11/6/2014)... yet progress in preventing and treating migratory cancer ... challenging to design drugs that work against metastasis," ... at Harvard Medical School. , "Unfortunately, many ... , Gujral and colleagues have now identified a ... how metastasis begins. Their findings may also inform ...
(Date:11/5/2014)... de Janeiro, Brazil -Individuals show great diversity in their ... males and females greatly differ in their perceptual evaluation ... of smell tests. , Sex differences in ... behaviors and may be connected to one,s perception of ... emotions. Thus, women,s olfactory superiority has been suggested to ...
Breaking Biology News(10 mins):Study finds laundry detergent pods, serious poisoning risk for children 2Migration negation 2Migration negation 3The female nose always knows: Do women have more olfactory neurons? 2
... "It,s in their genes" is a common refrain from ... age 100 and beyond. Up until now, research has ... as high levels of HDL ("good") cholesterol. But researchers at ... Graduate School of Psychology of Yeshiva University have found ...
... have discovered that some hardy species can survive the ... submersible rises to the surface. The team,s findings, published ... can be inadvertently carried by submersibles to new areas, ... using the manned submersible Alvin to collect samples of ...
... DURHAM, N.C. Women receiving care for breast ... for years after they have completed treatment, according to ... Center. The findings, reported online in the ... that poor cardio-pulmonary function may be a strong predictor ...
Cached Biology News:'Personality genes' may help account for longevity 2Deep sea animals stowaway on submarines and reach new territory 2Cardio fitness levels of breast cancer patients may affect survival 2
... The standard electrophoresis hood ... gel documentation systems. Placed on ... camera in place and provides ... photography on the lab bench. ...
... microarrays are derived from frozen embedded tissue ... control procedures to ensure the highest quality. ... in one block, sectioned at a thickness ... slides. Sections are large (3-5 mm in ...
... derived from Paraffin embedded tissue blocks, which ... to ensure the highest quality. Tissues of ... block, sectioned at a thickness of 5 ... are large (3-5 mm in diameter) in ...
... tissue microarrays are derived from Paraffin embedded ... quality control procedures to ensure the highest ... assembled in one block, sectioned at a ... coated slides. Sections are large (3-5mm in ...
Biology Products: